Glenmark Life Sciences IPO - Leveraging API Base Towards Contract Development, Manufacturing: Dolat Capital
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital's IPO Report
Glenmark Life Sciences (a spin-off from Glenmark Pharmaceuticals Ltd.), operates in two segments – generic active pharmaceutical ingredients (91% of sales) and contract development and manufacturing (8% of sales) with dominance in chronic therapies such as cardiovascular system and central nervous system.
It currently has 120 molecules and 65% of customer base which is repeat in nature.
Major customers are Glenmark Pharma (contributes 35% of sales), Torrent Pharma Ltd., Teva, Aurobindo Pharma Ltd. and Krka.
With 65% of revenue coming from U.S./Europe, Glenmark Life Sciences intends to expand presence in regions that are moving towards becoming well-regulated markets such as South Korea, Taiwan, Russia, Brazil, Mexico and Saudi Arabia.
Click on the attachment to read the full IPO report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.